Hims & Hers Expands GLP-1 Treatment Options on Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: stocktwits
- Product Line Expansion: Hims & Hers has added Eli Lilly's Zepbound, Mounjaro, and Foundayo GLP-1 treatments to its platform, enhancing user choice and strengthening its competitive position in the telehealth market.
- Membership Pricing: Access to these treatments requires a membership fee of $39 for the first month and $149 thereafter, ensuring a steady revenue stream for the company while attracting more customers.
- Positive Market Reaction: Shares of Hims & Hers rose nearly 4% in opening trade following the announcement of the new offerings, indicating investor confidence in the company's strategic direction and growth potential.
- High Retail Sentiment: Retail sentiment on Stocktwits around Hims & Hers is trending in the 'extremely bullish' territory, with users expressing optimism about the stock's potential run-up before the next earnings report, reflecting a positive outlook on the company's future.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 29.010
Low
16.50
Averages
32.95
High
60.00
Current: 29.010
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Hims & Hers Launches Estrogen Patch Service for Menopause
- Estrogen Patch Supply: Hims & Hers Health has announced the availability of estrogen patches for women experiencing perimenopause and menopause through its Hers platform, starting at $134 per month, addressing the rising demand for hormone replacement therapy.
- Surge in Market Demand: With approximately 1.3 million women entering menopause annually, Hims stated that the outdated supply chain cannot keep up with a new generation of women eager to reclaim their health and vitality, making the Hers platform essential.
- FDA Policy Change: The FDA's removal of the 'black box' warning for hormone replacement therapy products related to menopause symptoms in November was highlighted by Hims as a victory for science over stigma, while also exposing a systemic crisis.
- Role as Health Partner: Hims emphasized that Hers aims to provide reliable health support for women experiencing perimenopause and menopause during this period of uncertainty, ensuring they have access to necessary treatments.
See More
Hims & Hers Expands GLP-1 Treatment Options on Platform
- Product Line Expansion: Hims & Hers has added Eli Lilly's Zepbound, Mounjaro, and Foundayo GLP-1 treatments to its platform, enhancing user choice and strengthening its competitive position in the telehealth market.
- Membership Pricing: Access to these treatments requires a membership fee of $39 for the first month and $149 thereafter, ensuring a steady revenue stream for the company while attracting more customers.
- Positive Market Reaction: Shares of Hims & Hers rose nearly 4% in opening trade following the announcement of the new offerings, indicating investor confidence in the company's strategic direction and growth potential.
- High Retail Sentiment: Retail sentiment on Stocktwits around Hims & Hers is trending in the 'extremely bullish' territory, with users expressing optimism about the stock's potential run-up before the next earnings report, reflecting a positive outlook on the company's future.
See More
Ro Launches Major Price Cuts, Increasing Competitive Pressure on HIMS
- Intensified Price Competition: Ro's Body Membership program offers up to 50% discounts for prepaid patients, translating to annual savings of $900, significantly lowering treatment costs and posing a threat to HIMS's market share.
- HIMS Stock Decline: Following Ro's price cuts, HIMS shares fell 3% in premarket trading on Thursday, marking its second consecutive day of losses, reflecting investor concerns over intensified competition as the stock price dropped to $29.01.
- Shifting Market Dynamics: With Amazon expanding its GLP-1 management program through One Medical, Bank of America Securities warned that this could exert long-term pressure on HIMS's weight-loss revenues, particularly among patients seeking lower-cost prescription renewals.
- Product Line Expansion: HIMS is diversifying its treatment portfolio by launching estrogen patch treatments for menopause and perimenopause care, indicating a strategic intent to broaden its offerings in response to market competition and patient needs.
See More
HIMS Expands Menopause Treatment Options Amid Supply Strains
- Surge in Demand: Rising U.S. demand for hormone therapy has strained supplies of estrogen patches, prompting HIMS to launch treatment options for menopause and perimenopause, despite facing a potential three-year shortage of medications.
- Stock Volatility: HIMS shares dropped nearly 5% on Wednesday, reflecting analysts' concerns over lower revenues in 2026, particularly due to Amazon's new GLP-1 program, which may pressure HIMS' revenue streams.
- Analyst Rating Changes: Bank of America raised HIMS' price target to $30 while maintaining a 'Neutral' rating, indicating cautious sentiment as analysts expect ongoing revenue constraints due to competition from Amazon, with mixed ratings from other analysts.
- Treatment Plan Details: HIMS has secured sufficient inventory of estrogen patches, which will be available immediately to eligible users through its Hers platform, starting at $134 per month, with treatment plans potentially including progesterone, thereby enhancing its service offerings.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
Hims & Hers Launches Estrogen Patch Service for Menopause
- Estrogen Patch Supply: Hims & Hers Health has announced the availability of estrogen patches for women experiencing perimenopause and menopause through its Hers platform, starting at $134 per month, addressing the rising demand for hormone replacement therapy.
- Surge in Market Demand: With approximately 1.3 million women entering menopause annually, Hims stated that the outdated supply chain cannot keep up with a new generation of women eager to reclaim their health and vitality, making the Hers platform essential.
- FDA Policy Change: The FDA's removal of the 'black box' warning for hormone replacement therapy products related to menopause symptoms in November was highlighted by Hims as a victory for science over stigma, while also exposing a systemic crisis.
- Role as Health Partner: Hims emphasized that Hers aims to provide reliable health support for women experiencing perimenopause and menopause during this period of uncertainty, ensuring they have access to necessary treatments.
See More
Hims & Hers Expands GLP-1 Treatment Options on Platform
- Product Line Expansion: Hims & Hers has added Eli Lilly's Zepbound, Mounjaro, and Foundayo GLP-1 treatments to its platform, enhancing user choice and strengthening its competitive position in the telehealth market.
- Membership Pricing: Access to these treatments requires a membership fee of $39 for the first month and $149 thereafter, ensuring a steady revenue stream for the company while attracting more customers.
- Positive Market Reaction: Shares of Hims & Hers rose nearly 4% in opening trade following the announcement of the new offerings, indicating investor confidence in the company's strategic direction and growth potential.
- High Retail Sentiment: Retail sentiment on Stocktwits around Hims & Hers is trending in the 'extremely bullish' territory, with users expressing optimism about the stock's potential run-up before the next earnings report, reflecting a positive outlook on the company's future.
See More
Ro Launches Major Price Cuts, Increasing Competitive Pressure on HIMS
- Intensified Price Competition: Ro's Body Membership program offers up to 50% discounts for prepaid patients, translating to annual savings of $900, significantly lowering treatment costs and posing a threat to HIMS's market share.
- HIMS Stock Decline: Following Ro's price cuts, HIMS shares fell 3% in premarket trading on Thursday, marking its second consecutive day of losses, reflecting investor concerns over intensified competition as the stock price dropped to $29.01.
- Shifting Market Dynamics: With Amazon expanding its GLP-1 management program through One Medical, Bank of America Securities warned that this could exert long-term pressure on HIMS's weight-loss revenues, particularly among patients seeking lower-cost prescription renewals.
- Product Line Expansion: HIMS is diversifying its treatment portfolio by launching estrogen patch treatments for menopause and perimenopause care, indicating a strategic intent to broaden its offerings in response to market competition and patient needs.
See More
HIMS Expands Menopause Treatment Options Amid Supply Strains
- Surge in Demand: Rising U.S. demand for hormone therapy has strained supplies of estrogen patches, prompting HIMS to launch treatment options for menopause and perimenopause, despite facing a potential three-year shortage of medications.
- Stock Volatility: HIMS shares dropped nearly 5% on Wednesday, reflecting analysts' concerns over lower revenues in 2026, particularly due to Amazon's new GLP-1 program, which may pressure HIMS' revenue streams.
- Analyst Rating Changes: Bank of America raised HIMS' price target to $30 while maintaining a 'Neutral' rating, indicating cautious sentiment as analysts expect ongoing revenue constraints due to competition from Amazon, with mixed ratings from other analysts.
- Treatment Plan Details: HIMS has secured sufficient inventory of estrogen patches, which will be available immediately to eligible users through its Hers platform, starting at $134 per month, with treatment plans potentially including progesterone, thereby enhancing its service offerings.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: President Trump announced the extension of the ceasefire with Iran, originally set to expire today, until Tehran presents a 'unified proposal,' aiming to ease tensions in the Middle East, which could impact global oil prices.
- Boeing Earnings Beat: Boeing reported a smaller-than-expected loss per share in Q1 and exceeded revenue expectations, leading to a more than 3% rise in its stock price, indicating a gradual recovery in a challenging aviation market that may boost investor confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for Federal Reserve Chair, faced tough questions during his confirmation hearing regarding his independence and financial background, despite asserting he wouldn't lower interest rates solely at Trump's request, potentially affecting market expectations for Fed policy.
- Best Buy's New CEO: Best Buy announced that insider Jason Bonfig will succeed CEO Corie Barry on October 31, tasked with driving sales amid a lukewarm market while the company seeks to enhance its presence in the artificial intelligence product sector.
See More
Trump Extends Ceasefire with Iran Amid Market Volatility
- Ceasefire Extension: Trump announced the extension of the ceasefire with Iran, originally set to expire today, now lasting until Tehran provides a 'unified proposal', aiming to alleviate market concerns over geopolitical risks, which could positively impact oil prices and stock markets.
- Boeing Stock Surge: Boeing shares rose over 3% this morning after the company reported a smaller-than-expected loss per share and exceeded revenue expectations in Q1, demonstrating resilience during tough times, with the CEO set to discuss results on CNBC today, further boosting market confidence.
- Fed Nominee Scrutiny: Kevin Warsh, Trump's nominee for the Federal Reserve chair, faced tough questions during his confirmation hearing, asserting he wouldn't lower interest rates at Trump's request, raising concerns about his independence and financial background, which may influence market expectations for future monetary policy.
- Amazon Enters GLP-1 Market: Amazon's primary care arm launched a new program to ease access to weight-loss drugs, enhancing its competitiveness in the healthcare sector while potentially boosting the market performance of related stocks, reflecting the company's strategic expansion into pharmaceuticals.
See More
